Characterization of HER2‐low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study
Sign Up to like & getrecommendations! Published in 2024 at "Cancer"
DOI: 10.1002/cncr.35323
Abstract: Breast cancer (BC) in women aged ≤40 years carrying germline pathogenetic variants (PVs) in BRCA1/2 genes is infrequent but often associated with aggressive features. Human epidermal growth factor receptor 2 (HER2)‐low‐expressing BC has recently emerged… read more here.
Keywords: cancer; breast cancer; characterization her2; her2 low ... See more keywords
Preoperative Differentiation of HER2‐Zero and HER2‐Low from HER2‐Positive Invasive Ductal Breast Cancers Using BI‐RADS MRI Features and Machine Learning Modeling
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Magnetic Resonance Imaging"
DOI: 10.1002/jmri.29447
Abstract: Accurate determination of human epidermal growth factor receptor 2 (HER2) is important for choosing optimal HER2 targeting treatment strategies. HER2‐low is currently considered HER2‐negative, but patients may be eligible to receive new anti‐HER2 drug conjugates. read more here.
Keywords: zero her2; her2 low; her2; differentiation her2 ... See more keywords
The association between HER2-low status and survival in patients with metastatic breast cancer treated with Cyclin-dependent kinases 4 and 6 inhibitors: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2024 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-023-07226-1
Abstract: The cyclin-dependent kinase (CDK) 4/6 inhibitors significantly altered the treatment landscape of hormone-positive (HR+), HER2- metastatic breast cancer (MBC). However, biomarkers predicting long-term benefit and early progression are yet to be defined. Several studies suggested… read more here.
Keywords: breast cancer; her2 low; meta; review ... See more keywords
Evolution of low HER2 expression between early and advanced-stage breast cancer.
Sign Up to like & getrecommendations! Published in 2022 at "European journal of cancer"
DOI: 10.1016/j.ejca.2021.12.022
Abstract: BACKGROUND Low human epidermal growth factor receptor 2 (HER2) expression is emerging as an actionable biomarker for the treatment of breast cancer (BC) with novel anti-HER2 drugs. However, the evolution of this biomarker during the… read more here.
Keywords: her2 expression; expression; breast cancer; her2 low ... See more keywords
Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond.
Sign Up to like & getrecommendations! Published in 2020 at "Seminars in cancer biology"
DOI: 10.1016/j.semcancer.2020.02.016
Abstract: The human epidermal growth factor receptor 2 (HER2) is a well-known negative prognostic factor in breast cancer and a target of the monoclonal antibody trastuzumab as well as of other anti-HER2 compounds. Pioneering works on… read more here.
Keywords: her2 low; breast; breast cancer; evaluation ... See more keywords
Multi-institutional report of trastuzumab deruxtecan and stereotactic radiosurgery for HER2 positive and HER2-low breast cancer brain metastases
Sign Up to like & getrecommendations! Published in 2024 at "NPJ Breast Cancer"
DOI: 10.1038/s41523-024-00711-w
Abstract: Trastuzumab-deruxtecan (T-DXd) has demonstrated intracranial efficacy; however, safety and efficacy data remains limited with stereotactic radiosurgery (SRS). A multi-institutional review was performed with HER2+ or HER2-low metastatic breast cancer treated with T-DXd and SRS for… read more here.
Keywords: trastuzumab deruxtecan; her2; her2 low; breast cancer ... See more keywords
The Breast Cancer Classifier refines molecular breast cancer classification to delineate the HER2-low subtype
Sign Up to like & getrecommendations! Published in 2025 at "NPJ Breast Cancer"
DOI: 10.1038/s41523-025-00723-0
Abstract: Current breast cancer classification methods, particularly immunohistochemistry and PAM50, face challenges in accurately characterizing the HER2-low subtype, a therapeutically relevant entity with distinct biological features. This notable gap can lead to misclassification, resulting in inappropriate… read more here.
Keywords: classification; breast cancer; her2 low; breast ... See more keywords
HER2-low breast cancer is immune-cold: insights into tumor-infiltrating immune cells and implications for immunotherapy.
Sign Up to like & getrecommendations! Published in 2025 at "NPJ breast cancer"
DOI: 10.1038/s41523-025-00867-z
Abstract: This study investigated, for the first time, the association between HER2 expression, immune infiltration inferred by CIBERSORTx, and immunotherapy response in HER2-negative early breast cancer (EBC). Gene expression was analyzed in prospective discovery (n = 104), confirmatory… read more here.
Keywords: her2; her2 low; her2 expression; breast cancer ... See more keywords
A gene expression-based classifier for HER2-low breast cancer
Sign Up to like & getrecommendations! Published in 2024 at "Scientific Reports"
DOI: 10.1038/s41598-024-52148-7
Abstract: In clinical trials evaluating antibody-conjugated drugs (ADCs), HER2-low breast cancer is defined through protein immunohistochemistry scoring (IHC) 1+ or 2+ without gene amplification. However, in daily practice, the accuracy of IHC is compromised by inter-observer variability. Herein,… read more here.
Keywords: gene expression; her2; her2 low; low signature ... See more keywords
HER2-low breast cancers: Current insights and future directions.
Sign Up to like & getrecommendations! Published in 2022 at "Seminars in diagnostic pathology"
DOI: 10.1053/j.semdp.2022.07.003
Abstract: In light of the significant clinical benefits of novel HER2-targeting antibody-drug conjugates in advanced HER2-low expressing breast cancers in recent phases I and III clinical trials, particularly trastuzumab-deruxtecan (T-Dxd), the new "HER2-low" category in breast… read more here.
Keywords: low breast; breast; pathology; her2 low ... See more keywords
HER2 Low Status and Intratumoral Heterogeneity in Epithelial Malignancies and Their Therapeutic Implications
Sign Up to like & getrecommendations! Published in 2025 at "Indian Journal of Medical and Paediatric Oncology"
DOI: 10.1055/s-0045-1812851
Abstract: Abstract Human epidermal growth factor receptor 2 (HER2) continues to serve as a critical biomarker in breast cancer, but the introduction of evolving classifications such as HER2-low and HER2-ultra-low presents both opportunities and challenges in… read more here.
Keywords: oncology; her2 low; low status; status intratumoral ... See more keywords